Yanagisawa Ryu, Koizumi Tomonobu, Koya Terutsugu, Sano Kenji, Koido Shigeo, Nagai Kazuhiro, Kobayashi Masanori, Okamoto Masato, Sugiyama Haruo, Shimodaira Shigetaka
Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan
Shinshu Cancer Center, Shinshu University Hospital, Matsumoto, Japan.
Anticancer Res. 2018 Apr;38(4):2217-2225. doi: 10.21873/anticanres.12464.
BACKGROUND/AIM: Wilms' tumor 1 (WT1) is a tumor-associated antigen highly expressed in cancer. We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer.
Eight patients with resectable pancreatic cancer undergoing surgery either combined with S-1 or S-1 plus gemcitabine therapy were enrolled. Immunohistochemical analysis of WT1 was performed in 34 cases of pancreatic cancer.
No serious side-effects were observed, except grade I fever in five and grade I reactions at the injection site in all patients. WT1-specific cytotoxic T-lymphocytes were detected in seven patients, and WT1 and human leukocyte antigen class I antigens were positive in all 34 cases.
Our study clarified the safety and potential acquisition of immunity after vaccination targeting WT1. Further efficacy of WT1-DC vaccine to improve prognosis would be determined by a prospective clinical trial for resectable pancreatic cancer.
背景/目的：肾母细胞瘤1（WT1）是一种在癌症中高度表达的肿瘤相关抗原。我们研究了WT1肽脉冲树突状细胞（WT1-DC）疫苗联合化疗用于接受手术切除的胰腺癌患者的安全性。
招募了8例接受手术切除且正在接受S-1或S-1加吉西他滨治疗的可切除胰腺癌患者。对34例胰腺癌患者进行了WT1的免疫组织化学分析。
除5例患者出现I级发热和所有患者注射部位出现I级反应外，未观察到严重副作用。7例患者检测到WT1特异性细胞毒性T淋巴细胞，34例患者的WT1和人类白细胞抗原I类抗原均呈阳性。
我们的研究阐明了针对WT1接种疫苗后的安全性和潜在免疫获得情况。WT1-DC疫苗改善预后的进一步疗效将通过可切除胰腺癌的前瞻性临床试验来确定。
